메뉴 건너뛰기




Volumn 94, Issue 1, 2015, Pages 74-78

Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells

Author keywords

Chronic myeloid leukaemia; HOCT1; Imatinib; Pregnane X receptor; Retinoid acid receptor; Retinoid X receptor

Indexed keywords

ALITRETINOIN; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; HUMAN ORGANIC CATION TRANSPORTER 1; IMATINIB; LIVER X RECEPTOR ALPHA; MINERALOCORTICOID RECEPTOR; ORGANIC CATION TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; RETINOIC ACID; RETINOID ACID RECEPTOR; RETINOID X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG; VITAMIN RECEPTOR; STEROID RECEPTOR;

EID: 84922867413     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12409     Document Type: Article
Times cited : (11)

References (19)
  • 1
    • 84878490313 scopus 로고    scopus 로고
    • A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia
    • Francis S, Lucas CM, Wang L, et al. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. Leuk Res 2013;37:752-8.
    • (2013) Leuk Res , vol.37 , pp. 752-758
    • Francis, S.1    Lucas, C.M.2    Wang, L.3
  • 2
    • 78650676294 scopus 로고    scopus 로고
    • EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
    • Daghistani M, Marin D, Khorashad JS, et al. EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood 2010;116:6014-7.
    • (2010) Blood , vol.116 , pp. 6014-6017
    • Daghistani, M.1    Marin, D.2    Khorashad, J.S.3
  • 3
    • 38349193809 scopus 로고    scopus 로고
    • Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
    • Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258-64.
    • (2008) Clin Pharmacol Ther , vol.83 , pp. 258-264
    • Wang, L.1    Giannoudis, A.2    Lane, S.3
  • 4
    • 37049028176 scopus 로고    scopus 로고
    • Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
    • White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064-72.
    • (2007) Blood , vol.110 , pp. 4064-4072
    • White, D.L.1    Saunders, V.A.2    Dang, P.3
  • 5
    • 1842717950 scopus 로고    scopus 로고
    • Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome
    • Zhang Z, Burch P, Cooney A, et al. Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. Genome Res 2004;14:580-90.
    • (2004) Genome Res , vol.14 , pp. 580-590
    • Zhang, Z.1    Burch, P.2    Cooney, A.3
  • 6
    • 84866319957 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells
    • Wang L, Giannoudis A, Austin G, et al. Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. Exp Hematol 2012;40:811-9.
    • (2012) Exp Hematol , vol.40 , pp. 811-819
    • Wang, L.1    Giannoudis, A.2    Austin, G.3
  • 7
    • 9444282642 scopus 로고    scopus 로고
    • Active transport of imatinib into and out of cells: implications for drug resistance
    • Thomas J, Wang L, Clark R, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45.
    • (2004) Blood , vol.104 , pp. 3739-3745
    • Thomas, J.1    Wang, L.2    Clark, R.3
  • 8
    • 0038000046 scopus 로고    scopus 로고
    • The nuclear pregnane X receptor regulates xenobiotic detoxification
    • Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 2003;133:2444S-7S.
    • (2003) J Nutr , vol.133 , pp. 2444S-2447S
    • Kliewer, S.A.1
  • 9
    • 34548059857 scopus 로고    scopus 로고
    • Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats
    • Maeda T, Oyabu M, Yotsumoto T, et al. Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. Drug Metab Dispos 2007;35:1580-6.
    • (2007) Drug Metab Dispos , vol.35 , pp. 1580-1586
    • Maeda, T.1    Oyabu, M.2    Yotsumoto, T.3
  • 10
    • 59149090185 scopus 로고    scopus 로고
    • Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor
    • Köhle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 2009;77:689-99.
    • (2009) Biochem Pharmacol , vol.77 , pp. 689-699
    • Köhle, C.1    Bock, K.W.2
  • 11
    • 79951812086 scopus 로고    scopus 로고
    • Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants
    • Cho SK, Yoon JS, Lee MG, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011;89:416-21.
    • (2011) Clin Pharmacol Ther , vol.89 , pp. 416-421
    • Cho, S.K.1    Yoon, J.S.2    Lee, M.G.3
  • 12
    • 34548350509 scopus 로고    scopus 로고
    • Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity
    • Lemaire G, Benod C, Nahoum V, et al. Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol Pharmacol 2007;723:572-81.
    • (2007) Mol Pharmacol , vol.723 , pp. 572-581
    • Lemaire, G.1    Benod, C.2    Nahoum, V.3
  • 13
  • 14
    • 84873744673 scopus 로고    scopus 로고
    • Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes
    • Le Vee M, Jouan E, Stieger B, et al. Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes. Eur J Pharm Sci 2013;48:767-74.
    • (2013) Eur J Pharm Sci , vol.48 , pp. 767-774
    • Le Vee, M.1    Jouan, E.2    Stieger, B.3
  • 15
    • 84865555252 scopus 로고    scopus 로고
    • Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation
    • Gocek E, Marchwicka A, Baurska H, et al. Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation. J Steroid Biochem Mol Biol 2012;132:220-6.
    • (2012) J Steroid Biochem Mol Biol , vol.132 , pp. 220-226
    • Gocek, E.1    Marchwicka, A.2    Baurska, H.3
  • 16
    • 24344482346 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of imatinib
    • Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-94.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 879-894
    • Peng, B.1    Lloyd, P.2    Schran, H.3
  • 17
    • 0037443754 scopus 로고    scopus 로고
    • MDR1 gene overexpression confers resistance to imatinibmesylate in leukemia cell line models
    • Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinibmesylate in leukemia cell line models. Blood 2003;101:2368-73.
    • (2003) Blood , vol.101 , pp. 2368-2373
    • Mahon, F.X.1    Belloc, F.2    Lagarde, V.3
  • 18
    • 0442313672 scopus 로고    scopus 로고
    • Effect of rifampicin on the pharmacokinetics of imatinibmesylate (Gleevec, STI571) in healthy subjects
    • Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinibmesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-6.
    • (2004) Cancer Chemother Pharmacol , vol.53 , pp. 102-106
    • Bolton, A.E.1    Peng, B.2    Hubert, M.3
  • 19
    • 35948961894 scopus 로고    scopus 로고
    • Human pregnane X receptor and resistance to chemotherapy in prostate cancer
    • Chen Y, Tang Y, Wang MT, et al. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res 2007;67:10361-7.
    • (2007) Cancer Res , vol.67 , pp. 10361-10367
    • Chen, Y.1    Tang, Y.2    Wang, M.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.